Depo-Provera mass-tort narrative is scaling - even before verdicts, the overhang can reprice sentiment
The Opportunity
The thesis here is not about clinical efficacy; it is about litigation scale and narrative persistence. The underlying report frames a long-duration usage story and ties it to a growing plaintiff set, which is precisely the setup where investor psychology can move ahead of court resolution: a slow legal process, but a fast reputational and risk-premium response. 7A resolves the direction SHORT on a pharma proxy because mass-tort narratives can keep sector sentiment capped even when hard damages are not yet crystallised.
The Timing
Mixed 55 regime with crosswind 60 is a poor environment for relying on a single headline to drive a clean move, but litigation narratives do not need one-day gaps; they work through cumulative salience. Freshness is 60/100 with an access constraint noted upstream (page access error in the run), so the key tripwire is docket-level validation: MDL structure, trial schedule updates, and any company disclosure that quantifies exposure or reserves.
The Evidence
Hydrated evidence in this cycle is the NJ.com story at nj.com . 7A notes the filing context (December 2024) and a reported trial schedule (December 2025), and flags that validation overlays are unconfirmed due to upstream truncation, so the evidentiary base here is the reporting itself rather than practitioner corroboration.